<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04113772</url>
  </required_header>
  <id_info>
    <org_study_id>Global CRO Orfadin</org_study_id>
    <nct_id>NCT04113772</nct_id>
  </id_info>
  <brief_title>Bio Equivalency 20 Mgm Orfadin and 20 Mgm of Nitisonine</brief_title>
  <acronym>Orfadin</acronym>
  <official_title>Orfadin and Nitinosine Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sutphin Drugs</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sutphin Drugs</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      he purpose of this study is to determine whether Nitisinone 10 mg Tablets (Test Product are&#xD;
      bioequivalent to the reference product Orfadin 10 mg&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Detailed Description:&#xD;
&#xD;
      The specific aim is to conduct a randomized, single dose, three-period crossover&#xD;
      bioequivalence study in at least 18 healthy male and female subjects at a single study center&#xD;
      to evaluate the in vivo performance of two formulations of Nitisinone 10 mg and the reference&#xD;
      product Orfadin under fasting.&#xD;
&#xD;
      A total of 4 healthy female and male volunteers (age 18 to 55 years old) will be entered into&#xD;
      the study. Volunteers will be determined to be free of significant medical conditions as&#xD;
      assessed by medical history, physical examination, and blood and urine tests. Volunteers will&#xD;
      be randomly allocated to a treatment sequence, before administration of investigational&#xD;
      nitinosine&#xD;
&#xD;
      Determination of succinylacetone (SA) in blood (serum/plasma) and/or urine will be performed.&#xD;
      Results from samples analyzed at the central laboratory, including determination of&#xD;
      nitisinone, will be used in the evaluation of pharmacokinetics, efficacy and safety during&#xD;
      the two treatment periods.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date type="Anticipated">November 1, 2019</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Succinylacetone level</measure>
    <time_frame>8 weeks</time_frame>
    <description>Succinylacetone level will be measured every 2 weeks for eight weeks</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">4</enrollment>
  <condition>Hereditary Tyrosinemia, Type I</condition>
  <arm_group>
    <arm_group_label>Orfandin .5 mgm/kg mgm bid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Two participant will receive .5 mgm/kg mgm of orfadin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nitinosine .5 mgm/kg bid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two participant will receive .5 mgm/kg of nitinosine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nitisinone</intervention_name>
    <description>Measure bio equivalency/efficacy of nitinosine and orfadin</description>
    <arm_group_label>Nitinosine .5 mgm/kg bid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Orfadin</intervention_name>
    <description>Orfadin</description>
    <arm_group_label>Orfandin .5 mgm/kg mgm bid</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  All HT-1 patients receiving Orfadin treatment are eligible for entry.&#xD;
&#xD;
          -  Male and female patients of all ages diagnosed with HT-1.&#xD;
&#xD;
          -  Stable lab values, including liver values &lt;2 ULN (ALP, ALT, AST, bilirubin, INR).&#xD;
&#xD;
          -  Women of childbearing potential willing to use adequate contraception&#xD;
&#xD;
          -  Signed informed consent/assent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any medical condition which in the opinion of the investigator makes the patient&#xD;
             unsuitable for inclusion.&#xD;
&#xD;
          -  Enrollment in another concurrent clinical interventional study within three months&#xD;
             prior to inclusion in this study.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Lactating women. .Known hepatitis B, hepatitis C or HIV infection.&#xD;
&#xD;
          -  Foreseeable inability to cooperate with given instructions or study procedures.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ajai Prakash</last_name>
    <phone>7185260310</phone>
    <email>ajaiprakashny@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Lifein Multi-Specialty Hospital</name>
      <address>
        <city>Navsari</city>
        <state>Gujarat</state>
        <zip>396421</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 1, 2019</study_first_submitted>
  <study_first_submitted_qc>October 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 3, 2019</study_first_posted>
  <last_update_submitted>October 2, 2019</last_update_submitted>
  <last_update_submitted_qc>October 2, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">October 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tyrosinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitisinone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

